Humana Inc. (HUM) Monthly Stock Report
Publication Date: September 22, 2024
Company Overview
Humana Inc. (HUM), based in Louisville, Kentucky, is a leading healthcare company founded in 1961, originally as Extendicare Inc. The firm specializes in providing diverse healthcare plans, including medical, supplemental, dental, vision, life insurance, and pharmacy benefit management services. Catering to individuals, employers, and government programs like Medicaid and Medicare, Humana is committed to managed healthcare, continuously innovating with additions such as home health and hospice services. With robust total revenues of approximately $112.04 billion, Humana showcases its strong financial performance and potential as a noteworthy investment option.
Investment Analysis
In the current healthcare plans industry, Humana presents a compelling investment opportunity. With a current stock price of $310.41 and a target high price set at $439.00, analysts recommend a “buy” rating based on projected growth and profitability. This optimism is reinforced by a target mean price of $392.01, indicating a promising appreciation potential as it is considerably lower than its 52-week high of $530.54. Furthermore, the company exhibits a low short interest of 2,114,247 shares, or about 1.76% of its float, suggesting that the majority of investors remain bullish. However, better insights into earnings metrics, particularly EBITDA, are needed for a complete assessment of the company’s operating performance.
Market Performance
Humana’s stock reflects volatility within a range marked by its 52-week low of $298.61. Currently, it trades below its 50-day moving average of $358.26, signifying a bearish trend. This positioning suggests caution among investors amid fluctuating confidence levels. The consensus from 21 analysts, with a mean recommendation score of 2.4, indicates optimism toward Humana’s growth prospects, further solidified by a target low price of $349.00. As healthcare remains a dynamic sector, ongoing developments will be crucial in shaping Humana’s performance moving forward.
Disclaimer: This report is for informational purposes only and should not be construed as financial advice. Always conduct your own research before making investment decisions.
| Metric | Value |
|---|---|
| Market Cap | $37.4b |
| Total Debt | $13.3b |
| Total Cash | $22.9b |
| Shares Outstanding | 120.4m |
| Float Shares | 120.0m |
Disclaimer:
The information provided in this monthly report is for informational purposes only and should not be construed as financial, investment, or trading advice. AltStation.io does not guarantee the accuracy, completeness, or timeliness of the data and analyses presented. The content is based on publicly available information, and while we strive to ensure its accuracy, errors and omissions may occur.
Investing in stocks, cryptocurrencies, and other financial instruments involves significant risk, including the potential loss of principal. Past performance is not indicative of future results. Readers should conduct their own research and consult with a qualified financial advisor before making any investment decisions. AltStation.io and its affiliates are not responsible for any losses incurred as a result of using this report.
By using this report, you acknowledge that you understand and accept these terms.